WOBURN, Mass. (July 10, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that the U.S. Food and Drug Administration (FDA) has approved Katerzia (amlodipine) Oral Suspension, 1 mg/mL, the first and only FDA-approved amlodipine oral suspension. Katerzia is indicated […]
WOBURN, Mass. (Jun. 12, 2019) – CutisPharma, Inc. announced today its acquisition of Silvergate Pharmaceuticals, Inc. and the unveiling of its new corporate brand for the unified company: Azurity Pharmaceuticals.
WOBURN, Mass. (Mar. 26, 2019) – CutisPharma, Inc. announced today the opening of its new corporate headquarters in Woburn, Mass. along with an expansion of its manufacturing operations at its existing location in Wilmington, Mass. The announcement was made at a grand opening ceremony held on Tuesday, March 26, 2019, and attended by the Honorable […]
WILMINGTON, Mass. (Mar. 25, 2019) – CutisPharma, Inc. announced today the commercial availability of FIRST-Atenolol grape-flavored oral solution compounding kit. FIRST-Atenolol provides pharmacists with a convenient, high-quality, standardized way to compound an oral liquid Atenolol solution for patients who are not otherwise served by commercially available therapies, such as those who are unable to swallow […]
WILMINGTON, Mass. (Apr. 2, 2018) – CutisPharma announced today the commercial launch of FIRVANQ ™ (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.
WILMINGTON, Mass. (Mar. 26, 2018) – CutisPharma, Inc. (“CutisPharma”), a specialty pharmaceutical company that for two decades has been the industry leader in providing innovative solutions to pharmacists, with its recently approved 505(b)(2) NDA for FIRVANQ ™ vancomycin oral solution kit by the FDA, today announced that it has been acquired by NovaQuest Capital Management, […]
Unrestricted Grant from Company to Support Awareness and Advocacy Efforts
WILMINGTON, Mass. (November 1, 2017) – – CutisPharma and the C Diff Foundation announced the launch of a
partnership today, the first day of Clostridium difficile awareness month. As part of the partnership, CutisPharma will award an unrestricted grant to the Foundation to further support its […]
Robert M. Palladino named as Chief Financial Officer, Dr. Yatindra Joshi as Special Advisor to the Board of Directors to accelerate Strategic Growth Plan activities.
WILMINGTON, Mass. (August 1, 2017) – CutisPharma today announced the appointments of Robert M. Palladino as Chief Financial Officer and Yatindra Joshi, Ph.D., as a Special Advisor to the Board of […]
Massachusetts Senator Bruce Tarr Joins Commemoration of Company’s Acceleration of Pipeline Development for FDA Approvals
WILMINGTON, Mass. (November 15, 2016) – CutisPharma today announced the opening of a Research and Development center to house the company’s expanding R&D team. The new center will provide office and laboratory space to facilitate the company’s aggressive plans for […]
Filling of Key Role Accelerates Company’s Efforts to Develop Drug Portfolio Toward NDA Filings and FDA Approvals
WILMINGTON, Mass. (August 1, 2016) – CutisPharma today announced the appointment of Steven Dinh, Sc.D., as Executive Vice President and Chief Scientific Officer. In this key role, Dinh will oversee the Company’s efforts to develop its pipeline of drugs […]
Hear CEO Neal Muni’s thoughts about changes to the compounding landscape in his interview with Bloomberg News.
Click here for link to interview (begins at 20:35): http://www.bloomberg.com/news/audio/2016-07-26/the-bloomberg-baystate-business-hour-biogen-convention
Joint development agreement will accelerate NDA filing and worldwide commercialization.
WILMINGTON, Mass. (April 5, 2016) – CutisPharma, a specialty pharmaceutical company that has historically developed and distributed kits used by pharmacists to safely create compounded medications, announced today that it is entering into Active Pharmaceutical Ingredient (API) supply and joint development agreements with Dr. Reddy’s Laboratories […]
Neal Muni, MD, MSPH is promoted to Chief Executive Officer.
Wilmington, MA (May 19, 2015) – CutisPharma, a specialty pharmaceutical company that develops and distributes bulk drugs in kits used by pharmacists to create compounded medications, today named President Neal Muni, MD, MSPH to the role of Chief Executive Officer.
Neal Muni replaces Indu Muni, Ph.D., who […]
CutisPharma, a specialty pharmaceutical company focusing on the development and commercialization of value-added kits for the compounding pharmacy market, announced today that it has closed an equity financing with Ampersand Capital Partners.
WILMINGTON, MA – January 6, 2015 – As a part of the transaction, Silicon Valley Bank has provided a senior credit facility to further […]
CutisPharma announced today that it has appointed Neal Muni, MD, MSPH as President and member of the Board of Directors. Dr. Muni will assume responsibility for overseeing the company’s commercial operations and guiding development strategy for it’s product portfolio.
WILMINGTON, MA – July 15, 2014 – “We are pleased that Neal has joined our team to […]
Use of FIRST® Kits facilitates compliance with USP Chapter
Woburn, Mass., December 19, 2012 – CutisPharma, Inc. today announced that the United States Patent and Trademark Office has issued a patent (US 8,276,757 B2) regarding a method for the preparation, storage and dispensing of compounded suppositories. The FIRST® container (suppository mold) and the method […]
US patent for the method of preparation, storage, and dispensing of compounded suppositories
Woburn, Mass., October 27, 2010 – CutisPharma, Inc. today announced that it has received approval from the United States Patent and Trademark Office for its patent (US 7,815,929) regarding a method for the preparation, storage and dispensing of compounded suppositories.
“By its very […]
Accreditation is designed to preserve the safety and integrity of the pharmaceutical supply chain
Woburn, Mass., June 23, 2009 – CutisPharma, Inc. announced today that it has received Verified Accredited Wholesale Distributors (VAWD) accreditation from the National Association of Boards of Pharmacy (NABP) for its Woburn, Massachusetts facility. In March 2007 the company received accreditation for […]